88394-05-2

Usage

Uses

Used in Organic Synthesis:
Pyrazinecarboxamide, 3,4-dihydro-5-methyl-3-oxo(9CI) is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of diverse chemical products, making it a valuable component in the development of new materials and pharmaceuticals.
Used in Pharmaceutical Development:
Due to its potential biological activities and pharmaceutical properties, Pyrazinecarboxamide, 3,4-dihydro-5-methyl-3-oxo(9CI) is used as a starting material for the development of new drugs. Its structure can be modified to create novel compounds with potential therapeutic applications, contributing to advancements in medicine and healthcare.
Used in Research and Development:
Pyrazinecarboxamide, 3,4-dihydro-5-methyl-3-oxo(9CI) is utilized in research and development settings to study its properties and potential applications. Scientists and researchers explore its chemical behavior, reactivity, and interactions with other compounds to gain insights into its possible uses and benefits.
Note: The specific applications and industries for Pyrazinecarboxamide, 3,4-dihydro-5-methyl-3-oxo(9CI) are not provided in the materials. The uses listed above are inferred based on the general potential of the compound as mentioned in the provided materials. Further research and investigation would be necessary to confirm these applications and identify specific industries where the compound is utilized.

InChI:InChI=1/C6H7N3O2/c1-3-2-8-4(5(7)10)6(11)9-3/h2H,1H3,(H2,7,10)(H,9,11)

Upstream product

• 62009-47-6 2-aminopropanediamide 
• 78-98-8 2-oxopropanal 

Downstream Products

• 43029-20-5 3-amino-6-methyl-2(1H)-pyrazinone 
• 120992-57-6 5-methyl-3-oxo-3,4-dihydro-pyrazine-2-carboxylic acid 
• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 120992-57-6 2-Hydroxy-6-methylpyrazine-3-carboxylic acid 
• 5521-57-3 5‐methylpyrazine-2-carboxamide 
• 5521-58-4 5-methylpyrazin-2-amine 
• 98006-91-8 5-methylpyrazine-2-carbonitrile 

Relevant academic research and scientific papers

Preparation method, product and application of 2-amino-5-methylpyrazine

The invention belongs to the field of chemical synthesis, and relates to a preparation method, product and application of 2-amino-5-methylpyrazine. The preparation method comprises the following steps: reacting 2-aminomalonamide with pyruvic aldehyde to generate 2-methyl-5-hydroxy-4-pyrazinamide; enabling 2-methyl-5-hydroxy-4-pyrazinamide to react with phosphorus oxychloride so as to generate 2-methyl-5-chloro-4-cyanopyrazine; carrying out a hydrogenation reaction on the 2-methyl-5-chloro-4-cyanopyrazine to generate 2-methyl-4-cyanopyrazine, and hydrolyzing the 2-methyl-4-cyanopyrazine to obtain 2-methyl-4-amide pyrazine; and carrying out Hofmann degradation on the 2-methyl-4-amide pyrazine so as to obtain the 2-methyl-5-aminopyrazine. The method belongs to a brand-new 2-amino-5-methylpyrazine preparation method, is simple and convenient to operate, high in yield and low in cost, and is suitable for industrial large-scale production.

Synthesis process of 2-methyl-5-pyrazinecarboxylic acid

The invention provides a method for preparing 2-methyl-5-pyrazinecarboxylic acid. The method provided by the invention is characterized in that potassium permanganate which is more harmful to the environment is not used, a target compound 2-methyl-5-pyrazinecarboxylic acid can be prepared from cheap and easily available methylglyoxal and 2-amino malonamide taken as raw materials through four stepsof cyclization, hydrolysis, chlorination and reduction, the yield of the reaction route is high, the amount of byproducts is small, and products are purer.

BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4', R5, R6, X, and n are described herein.